We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Phibro Animal Health (PAHC - Free Report) . Shares have lost about 6.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Phibro due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
PAHC Q4 Earnings & Revenues Beat Estimates
Phibro Animal Health reported adjusted earnings of 85 cents per share for the fourth quarter of fiscal 2026, up 35% year over year. The bottom line beat the Zacks Consensus Estimate of 72 cents by 18.1%.
PAHC Revenues
Net sales increased 5% year over year to $396.7 million and surpassed the consensus estimate by 8.4%. Higher sales, favorable product mix and tariff recoveries supported profitability. Adjusted gross margin expanded 380 basis points to 34.6%.
PAHC Issues Fiscal 2027 Guidance
For fiscal 2027, Phibro expects net sales between $1.55 billion and $1.60 billion, representing about 4% growth at the midpoint. The Zacks Consensus Estimate for the metric is pegged at $1.58 billion.
Adjusted earnings are expected in the range of $3.41-$3.59 per share, representing 9% growth at the midpoint. The Zacks Consensus Estimate is pegged at $3.43.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, Phibro has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Interestingly, Phibro has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report?
A month has gone by since the last earnings report for Phibro Animal Health (PAHC - Free Report) . Shares have lost about 6.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Phibro due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
PAHC Q4 Earnings & Revenues Beat Estimates
Phibro Animal Health reported adjusted earnings of 85 cents per share for the fourth quarter of fiscal 2026, up 35% year over year. The bottom line beat the Zacks Consensus Estimate of 72 cents by 18.1%.
PAHC Revenues
Net sales increased 5% year over year to $396.7 million and surpassed the consensus estimate by 8.4%. Higher sales, favorable product mix and tariff recoveries supported profitability. Adjusted gross margin expanded 380 basis points to 34.6%.
PAHC Issues Fiscal 2027 Guidance
For fiscal 2027, Phibro expects net sales between $1.55 billion and $1.60 billion, representing about 4% growth at the midpoint. The Zacks Consensus Estimate for the metric is pegged at $1.58 billion.
Adjusted earnings are expected in the range of $3.41-$3.59 per share, representing 9% growth at the midpoint. The Zacks Consensus Estimate is pegged at $3.43.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, Phibro has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Interestingly, Phibro has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.